- News & Analysis
- Home
- Latest News
- Reports
- Podcasts
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Health
Aura rises to public markets
The Lundbeck, Chiesi Group and Li-Cor Biosciences-backed eye and bladder cancer therapeutics developer has filed to go public on Nasdaq in an offering with a $100m placeholder target.
Oct 13, 2021Daily Deal Round Up: October 12, 2021
Mobiliar took part in a $35m round for medicine transportation system developer SkyCell while Nice Investment co-led wealth management software provider Fount's $33.4m series C.
Oct 12, 2021MicroTech Medical meditates on $254m IPO plans
Eli Lilly, Taikang and Tencent are in line to exit the diabetes equipment maker, which has filed to go public in Hong Kong next week.
Oct 12, 2021Virgin Pulse to buy Welltok
Itochu, Qualcomm, Hearst, Catholic Health Initiatives, TriZetto and IBM are all set to exit the health plan platform developer.
Oct 12, 2021Brave Care brightens up with $25m
Mednax led the paediatric healthcare provider's series B round, pushing its overall funding past the $40m mark.
Oct 12, 2021Daily Deal Round Up: October 11, 2021
Corporate-backed cloud networking software provider Pluribus pushed its total funding to at least $110m while IAG has exited Hyper Anna in an acquisition by Alteryx.
Oct 11, 2021Daily deal net: October 11, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Oct 11, 2021Neumora secures $500m in funding
Amgen, SoftBank and Alexandria Real Estate Equities helped the neurodegenerative disease drug developer publicly launch with $500m in funding.
Oct 11, 2021Pyxis progresses to stock market
Bayer, Pfizer and Ipsen-backed cancer therapeutics developer Pyxis Oncology priced its shares at the top of its range.
Oct 11, 2021Sonendo files for IPO in New York
The dental technology developer’s proposed listing on the New York Stock Exchange would mark an exit for Henry Crown and Company.
Oct 11, 2021Theseus Pharmaceuticals prices $160m IPO
The Ariad Pharmaceuticals-backed cancer therapeutics developer floated at the top of its range following $120m in venture funding.
Oct 11, 2021Pyxis progresses to stock market
Having priced its shares at the top of its range, UChicago spinout Pyxis Oncology suffered a drop on the first day of trading.
Oct 11, 2021Featured Content
GCVI Summit 2026 RewindRewatch the sessions, recap the learningsGCVI Summit 2026 Rewind
Rewatch the sessions, recap the learnings
The World of Corporate VenturingGCV's annual report on the state of the corporate investment sectorThe World of Corporate Venturing
GCV's annual report on the state of the corporate investment sector
GCV’s Rising Stars and Emerging Leaders 2026The talent pipeline in corporate venturing shows both momentum and staying power, as the industry comes of age.GCV’s Rising Stars and Emerging Leaders 2026
The talent pipeline in corporate venturing shows both momentum and staying power, as the industry comes of age.
About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits our membership, providing privileged access to all our services and resources.
Navigation


